# Inflammation and Coronary Endothelial Function

Study · id `cardio:ct-nct02366091` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02366091](<https://clinicaltrials.gov/study/NCT02366091>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02366091

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 111 participants.

## Technical summary

Registry record NCT02366091. Randomized; triple masking; primary purpose other. Start 2015-01 (actual); primary completion 2020-08-01 (actual). Results posted on 2021-10-21.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose other
- Phase: Phase 2
- Enrolled: 111 participants (enrolled count; ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Started: 2015-01 (actual) (ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Primary completion: 2020-08-01 (actual) (ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Completion: 2020-09-01 (actual) (ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Results first posted: 2021-10-21 (ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02366091, source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02366091-2021-10-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Inflammation and Coronary Endothelial Function
- Condition: Coronary Artery Disease
- Intervention (Drug): Methotrexate
- Intervention (Drug): Colchicine
- Intervention (Drug): Placebo
- Lead sponsor: Johns Hopkins University
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Colchicine (`cardio:colchicine`)
- Registry lists this organization as the lead sponsor: Johns Hopkins University (`cardio:org-johns-hopkins-university`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: 3c6a3137c7804d3d25b6a6547d0d918e7c642c18a65e04db874704681f903794
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
